Cel­gene and the sci­en­tist who cham­pi­oned fe­dra­tinib's rise from Sanofi's R&D grave­yard win FDA OK

Six years af­ter Sanofi gave it up for dead, the FDA has ap­proved the myelofi­bro­sis drug fe­dra­tinib, now owned by Cel­gene.

The drug will be sold as In­re­bic, and will soon land in the port­fo­lio at Bris­tol-My­ers Squibb, which is fi­nal­iz­ing a deal to ac­quire Cel­gene.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER